<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">JCI Insight</journal-id>
<journal-id journal-id-type="iso-abbrev">JCI Insight</journal-id>
<journal-id journal-id-type="publisher-id">JCI Insight</journal-id>
<journal-title-group>
<journal-title>JCI Insight</journal-title>
</journal-title-group>
<issn pub-type="epub">2379-3708</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30232282</article-id>
<article-id pub-id-type="pmc">6237228</article-id>
<article-id pub-id-type="publisher-id">120493</article-id>
<article-id pub-id-type="doi">10.1172/jci.insight.120493</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Serafini</surname>
<given-names>Peter R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Feyder</surname>
<given-names>Michael J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hightower</surname>
<given-names>Rylie M.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garcia-Perez</surname>
<given-names>Daniela</given-names>
</name>
<email>garc1987@ravens.benedictine.edu</email>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vieira</surname>
<given-names>Natássia M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5889-2169</contrib-id>
<name>
<surname>Lek</surname>
<given-names>Angela</given-names>
</name>
<email>Angela.Lek@yale.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gibbs</surname>
<given-names>Devin E.</given-names>
</name>
<email>degibbs@ucla.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moukha-Chafiq</surname>
<given-names>Omar</given-names>
</name>
<email>omoukha-chafiq@southernresearch.org</email>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Augelli-Szafran</surname>
<given-names>Corinne E.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kawahara</surname>
<given-names>Genri</given-names>
</name>
<email>gkawahar@tokyo-med.ac.jp</email>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5597-1141</contrib-id>
<name>
<surname>Widrick</surname>
<given-names>Jeffrey J.</given-names>
</name>
<email>Jeffrey.Widrick@childrens.harvard.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kunkel</surname>
<given-names>Louis M.</given-names>
</name>
<email>kunkel@enders.tch.harvard.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Alexander</surname>
<given-names>Matthew S.</given-names>
</name>
<email>malexander@peds.uab.edu</email>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Division of Genetics and Genomics at Boston Children’s Hospital, Boston, Massachusetts, USA.</aff>
<aff id="A2"><label>2</label>Department of Pediatrics, Division of Neurology at the University of Alabama at Birmingham and Children’s of Alabama, Birmingham, Alabama, USA.</aff>
<aff id="A3"><label>3</label>UAB Center for Exercise Medicine at the University of Alabama at Birmingham, Birmingham, Alabama, USA.</aff>
<aff id="A4"><label>4</label>Southern Research, Department of Chemistry, Birmingham, Alabama, USA.</aff>
<aff id="A5"><label>5</label>Department of Pathophysiology, Tokyo Medical University, Tokyo, Japan.</aff>
<aff id="A6"><label>6</label>Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.</aff>
<aff id="A7"><label>7</label>The Manton Center for Orphan Disease Research at Boston Children’s Hospital, Boston, Massachusetts, USA.</aff>
<aff id="A8"><label>8</label>Department of Genetics at the University of Alabama at Birmingham, Birmingham, Alabama, USA.</aff>
<author-notes>
<corresp>Address correspondence to: Matthew S. Alexander, University of Alabama at Birmingham, Children’s of Alabama, 1918 University Blvd. MCLM 464 Box 96, Birmingham, Alabama 35294, USA. Phone: 205.934.7790; Email: <email>malexander@peds.uab.edu</email>. Or to: Louis M. Kunkel, Boston Children’s Hospital, Harvard Medical School, 3 Blackfan Circle CLS15027.3, Boston, Massachusetts 02115, USA. Phone: 617.355.7576; Email: <email>kunkel@enders.tch.harvard.edu</email>.</corresp>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> LMK is a consultant for Pfizer Inc., Summit Corporation PLC, and Tarix Pharmaceuticals for muscle disease drug therapies. LMK is also a consultant for SynapDx Corporation for autism screening technologies. All other authors declare no conflicting interests.</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2018-09-20T09:00:00-0400" publication-format="electronic">
<day>20</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date date-type="collection" iso-8601-date="2018-09-20T09:00:00-0400" publication-format="electronic">
<day>20</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>20</day>
<month>9</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 0 months and
						0 days and was based on the <pub-date
						pub-type="epub"/>. -->
<volume>3</volume>
<issue>18</issue>
<elocation-id>e120493</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>2</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>7</day>
<month>8</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018, American Society for Clinical Investigation</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://insight.jci.org/articles/view/120493">This article is available online at https://insight.jci.org/articles/view/120493</self-uri>
<abstract>
<p>Zebrafish are a powerful tool for studying muscle function owing to their high numbers of offspring, low maintenance costs, evolutionarily conserved muscle functions, and the ability to rapidly take up small molecular compounds during early larval stages. Fukutin-related protein (FKRP) is a putative protein glycosyltransferase that functions in the Golgi apparatus to modify sugar chain molecules of newly translated proteins. Patients with mutations in the <italic>FKRP</italic> gene can have a wide spectrum of clinical symptoms with varying muscle, eye, and brain pathologies depending on the location of the mutation in the FKRP protein. Patients with a common L276I FKRP mutation have mild adult-onset muscle degeneration known as limb-girdle muscular dystrophy 2I (LGMD2I), whereas patients with more C-terminal pathogenic mutations develop the severe Walker-Warburg syndrome (WWS)/muscle-eye-brain (MEB) disease. We generated <italic>fkrp</italic>-mutant zebrafish that phenocopy WWS/MEB pathologies including severe muscle breakdowns, head malformations, and early lethality. We have also generated a milder LGMD2I-model zebrafish via overexpression of a heat shock–inducible human FKRP (L276I) transgene that shows milder muscle pathology. Screening of an FDA-approved drug compound library in the LGMD2I zebrafish revealed a strong propensity towards steroids, antibacterials, and calcium regulators in ameliorating FKRP-dependent pathologies. Together, these studies demonstrate the utility of the zebrafish to both study human-specific FKRP mutations and perform compound library screenings for corrective drug compounds to treat muscular dystrophies.</p>
</abstract>
<abstract abstract-type="graphical">
<p>
<graphic orientation="portrait" position="float" xlink:href="jciinsight-3-120493-g137.jpg"></graphic>
</p>
</abstract>
<abstract abstract-type="toc">
<p>Zebrafish deficient in fukutin-related protein, a model of dystroglycanopathies, was used to screen a drug library and identified corrective compounds.</p>
</abstract>
<kwd-group kwd-group-type="specialties">
<kwd>Muscle Biology</kwd>
</kwd-group>
<kwd-group kwd-group-type="keywords">
<kwd>Drug screens</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>NIH</funding-source>
<award-id>5R25NS089463</award-id>
</award-group>
<award-group>
<funding-source>NIH</funding-source>
<award-id>2T32HD071866-06</award-id>
</award-group>
<award-group>
<funding-source>LGMD2i Fund</funding-source>
<award-id>Direct Award</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Muscular Dystrophy Association</institution>
<institution-id>https://doi.org/10.13039/100005202</institution-id>
</institution-wrap>
</funding-source>
<award-id>418254</award-id>
</award-group>
<funding-statement>R.M.H. is a member of the RoadMap Scholars Program at UAB</funding-statement>
<funding-statement>R.M.H. is also supported by a T32 training fellowship sponsored by the University of Alabama at Birmingham Center for Exercise Medicine. Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health</funding-statement>
<funding-statement>L.M.K. was supported by a combined research grant from the LGMD2I Research Fund, the Samantha Brazzo Foundation, and Cure CMD</funding-statement>
<funding-statement>M.S.A. is supported by a grant from the Muscular Dystrophy Association.</funding-statement>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>